NEW BRUNSWICK, N.J., Sept. 28 /PRNewswire-USNewswire/ -- James M.
 Golubieski, president of Foundation Venture Capital Group, LLC, announced
 today that the company has made a $500,000 commitment to CellXplore, Inc.,
 a start-up company at the University of Medicine & Dentistry of New Jersey
 (UMDNJ) committed to breast cancer diagnostics.
     Kiran Madura, Ph.D., chief scientific officer of CellXplore and
 professor in the Department of Biochemistry at UMDNJ-Robert Wood Johnson
 Medical School (RWJMS), founded the company.
     CellXplore has identified several biomarkers that could help in the
 non- invasive diagnosis of breast cancer, using a biochemical analysis of
 blood samples to identify specific proteins found in those who have the
 disease. According to Dr. Madura, the eventual hope is that the strategy
 would not only be able to help diagnose breast and other cancers but might
 also be able to discriminate between different types and stages, which
 would be helpful in establishing targeted treatment plans for patients.
     "While we are currently focusing on breast cancer biomarkers, in the
 future we will investigate whether blood sample biomarkers can also be
 identified for the early diagnosis of major, debilitating illnesses such as
 muscle wasting disease and neurodegenerative conditions including
 Alzheimer's and Parkinson's Disease," he explained.
     George F. Heinrich, M.D., vice chair and CEO of Foundation Venture
 Capital Group, is enthusiastic about this new company and what the
 investment means for the University.
     "Our investment in CellXplore reinforces our strong relationship with
 UMDNJ and our willingness to invest in companies that might not otherwise
 receive support at this early stage," said Dr. Heinrich. "Dr. Madura and
 his company are developing very promising technology that has great
 potential in the diagnosis of cancer and other devastating diseases."
     Foundation Venture Capital Group was founded in 2006 to invest in
 commercially viable new start-up companies developing technology at the
 University of Medicine & Dentistry of New Jersey. CellXplore is its second
 investment within the past six months.
 
 

SOURCE Foundation Venture Capital Group, LLC